MUKILTEO, Wash., Dec. 18, 2007 (PRIME NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that its subsidiary, CombiMatrix Molecular Diagnostics (CMDX), has completed the clinical validation of the first of its ATScan(tm) suite of BAC (Bacterial Artificial Chromosome) array CGH (Comparative Genomic Hybridization) based tests. ATScan is designed to detect known genomic copy-number variations (CNVs) associated with Autism Spectrum Disorder (ASD) and this test is now available to physicians and consumers.
